MEDTECH: Separating the wheat from the chaff

MedTech, which has historically been a defensive sector, has once again stood its ground even as broader markets have been rattled by the pandemic.

But, digging into the details throws up interesting trends: the resilience is underpinned by clear extremes.

Hence, leveraging the right opportunities assumes a greater importance and is critical to outperformance.

At the upcoming webinar, we will dissect these conflicting trends and share some interesting stock ideas that are best suited to win in a COVID-stricken world.

AlphaValue’s analysts on the sector, Sumit Sayal, Virendra Chauhan and Martin Schnee, Ph.D., just released a new strategy piece on European Medtech companies, including : BioMérieux, Qiagen, Sartorius Stedim, Sartorius, Getinge, and Siemens Healthineers.

Access to report : click here

Subscribe to our blog


Let’s talk
Interested in our research and want to learn more?
Alphavalue Morning Market Tip
Q4 trading statement better than expected.
If one is not inclined to cut a bit of each A&D holding, and is intent on retaining all-weather Airb...
2026 starts as your typical financial year with high eps growth ambitions (+11%), most likely to be tri...